Hospital Clinic Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (39)

2024

  1. Author Correction: Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma (Scientific Reports, (2024), 14, 1, (4561), 10.1038/s41598-024-55287-z)

    Scientific Reports

  2. C-reactive protein-complement factor H axis as a biomarker of activity in early and intermediate age-related macular degeneration

    Frontiers in Immunology, Vol. 15

  3. Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma

    Scientific Reports, Vol. 14, Núm. 1

  4. Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI©

    Ophthalmology and Therapy, Vol. 13, Núm. 6, pp. 1669-1682

  5. XEN® 45 en el manejo quirúrgico del glaucoma en fases tempranas: estudio nacional de consenso según metodología Delphi

    Archivos de la Sociedad Española de Oftalmologia, Vol. 99, Núm. 3, pp. 98-108

2023

  1. Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)

    Ophthalmology and Therapy

  2. Diagnostic and Management Strategies of Tubulointerstitial Nephritis and Uveitis Syndrome (TINU): Current Perspectives

    Clinical Ophthalmology, Vol. 17, pp. 2625-2630

  3. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study

    International Ophthalmology, Vol. 43, Núm. 12, pp. 4639-4649

  4. Herpetic Anterior Uveitis Multicentre Longitudinal Study (The UVHER Project). Baseline Characteristics

    Ocular Immunology and Inflammation, Vol. 31, Núm. 7, pp. 1497-1504

  5. Spontaneous resolution of inflammatory epiretinal membrane: Case series and review of the literature

    European Journal of Ophthalmology, Vol. 33, Núm. 1, pp. NP10-NP14

  6. Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055

2022

  1. Guía de recomendaciones para el manejo de brolucizumab

    Archivos de la Sociedad Española de Oftalmologia, Vol. 97, Núm. 11, pp. 626-638

  2. Respuesta al comentario «El menosprecio de lo próximo», relativo al editorial «Inteligencia artificial y Oftalmología: Estado actual»

    Archivos de la Sociedad Española de Oftalmologia, Vol. 97, Núm. 7, pp. 418-419

2021

  1. Impacto de la infección por el nuevo coronavirus en los pacientes con uveítis asociada a una enfermedad autoinmune: resultado de la encuesta COVID-19-GEAS pacientes

    Archivos de la Sociedad Española de Oftalmologia, Vol. 96, Núm. 7, pp. 347-352

  2. Inteligencia artificial y oftalmología: estado actual

    Archivos de la Sociedad Española de Oftalmologia, Vol. 96, Núm. 8, pp. 399-400

  3. Multidisciplinary care and units for uveitis in the internal medicine departments in Spain: Survey of the Systemic Autoimmune Diseases Group

    Revista Clinica Espanola, Vol. 221, Núm. 4, pp. 221-225

  4. Recommendations for ophthalmologic practice during the easing of COVID-19 control measures

    Acta Ophthalmologica, Vol. 99, Núm. 7, pp. e973-e983

  5. Remote screening of retinal and optic disc diseases using handheld nonmydriatic cameras in programmed routine occupational health checkups onsite at work centers

    Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 259, Núm. 3, pp. 575-583

2020

  1. Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioÚvea) Study Group

    Ophthalmology

  2. Systemic Regulatory T Cells and IL-6 as Prognostic Factors for Anatomical Improvement of Uveitic Macular Edema

    Frontiers in Immunology, Vol. 11